Impact of adverse news media on prescriptions for osteoporosis: Effect on fractures and mortality

Medical Journal of Australia

Volumn 193, Issue 3, 2010, Pages 154-156

  Sambrook, Philip N ^a   Chen, Jiang S ^b   Simpson, Judy M ^c   March, Lyn M ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; DEATH; DRUG SAFETY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; MORTALITY; OSTEOPOROSIS; PRESCRIPTION; RISK FACTOR; TELEVISION VIEWING; AUSTRALIA; FRACTURES, BONE; HIP FRACTURES; STATISTICS AND NUMERICAL DATA; TELEVISION;

AUSTRALIA; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HIP FRACTURES; HUMANS; MORTALITY; PRESCRIPTIONS; TELEVISION;

EID: 77955744998     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03835.x     Document Type: Article

References (14)

1. Einarson A, Schachtschneider AK, Halil R, et al. SSRI's and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 2005; 5: 11.
2. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
3. McIntosh J, Blalock SJ. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005; 62: 69-74.
4. Yngve A, Hambraeus L, Lissner L, et al. The Women's Health Initiative. What is on trial: nutrition and chronic disease? Or misinterpreted science, media havoc and the sound of silence from peers? Public Health Nutr 2006; 9: 269-272.
5. Sambrook P. President's report. Aust N Z Bone Miner Soc Newsletter 2008; Issue 8: 1. http://www.anzbms.org.au/news/newsletters/ANZBMSnews-Apr08.pdf (accessed Sep 2008).
6. Garvan Institute. Fracture risk calculator. http://www.garvan.org.au/ promotions/bone-fracturerisk (accessed Sep 2008).
7. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155.
8. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD004523.
9. Black DM, Delmas PD, Eastell R, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
10. Center J, Nguyen T, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-882.
11. Fisher AA, O'Brien ED, Davis MW. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009; 45: 246-253.
12. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-1491.
13. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
14. Sambrook PN, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35: 801-803.